Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
203.4 EUR | -2.35% | -2.96% | -15.07% |
Apr. 23 | SARTORIUS STEDIM BIOTECH : Barclays reaffirms its Neutral rating | ZD |
Apr. 22 | Sartorius Stedim: in the red with brokerage comments | CF |
Sales 2024 * | 2.94B 3.15B | Sales 2025 * | 3.35B 3.59B | Capitalization | 19.79B 21.23B |
---|---|---|---|---|---|
Net income 2024 * | 343M 368M | Net income 2025 * | 459M 492M | EV / Sales 2024 * | 7.5 x |
Net Debt 2024 * | 2.27B 2.43B | Net Debt 2025 * | 2.15B 2.31B | EV / Sales 2025 * | 6.55 x |
P/E ratio 2024 * |
56.4
x | P/E ratio 2025 * |
40.7
x | Employees | 10,493 |
Yield 2024 * |
0.37% | Yield 2025 * |
0.54% | Free-Float | 31.97% |
Latest transcript on Sartorius Stedim Biotech
1 day | -2.35% | ||
1 week | -2.96% | ||
Current month | -23.04% | ||
1 month | -25.00% | ||
3 months | -10.59% | ||
6 months | +22.53% | ||
Current year | -15.07% |
Managers | Title | Age | Since |
---|---|---|---|
René Fáber
CEO | Chief Executive Officer | 48 | 19-03-25 |
Chairman | 59 | 07-06-28 | |
Chief Tech/Sci/R&D Officer | 59 | 09-04-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Henri Riey
BRD | Director/Board Member | 62 | 07-06-28 |
Chairman | 59 | 07-06-28 | |
Susan Dexter
BRD | Director/Board Member | 67 | 15-04-06 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.42% | 18 M€ | +3.76% | - | |
0.35% | 5 M€ | +4.56% |
Date | Price | Change | Volume |
---|---|---|---|
24-04-25 | 203.4 | -2.35% | 89,724 |
24-04-24 | 208.3 | -0.19% | 76,624 |
24-04-23 | 208.7 | +6.21% | 106,382 |
24-04-22 | 196.5 | -2.04% | 113,309 |
24-04-19 | 200.6 | -4.29% | 169,509 |
Real-time Euronext Paris, April 25, 2024 at 11:35 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-15.07% | 21.66B | |
-2.92% | 185B | |
-3.80% | 107B | |
-5.48% | 67.55B | |
+11.22% | 54.6B | |
+16.74% | 47.42B | |
+2.52% | 42.24B | |
+4.56% | 28.24B | |
+1.64% | 26.42B | |
+11.40% | 25.66B |
- Stock Market
- Equities
- DIM Stock